LEADER 03299nam 2200409 450 001 9910647231703321 005 20230323151526.0 010 $a3-0365-6122-6 035 $a(CKB)5680000000300026 035 $a(NjHacI)995680000000300026 035 $a(EXLCZ)995680000000300026 100 $a20230323d2023 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aFrontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis /$fby Michal Tomcik editor 210 1$a[Place of publication not identified] :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2023. 215 $a1 online resource (218 pages) 311 $a3-0365-6121-8 327 $aAbout the Editor vii -- Preface to "Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis " ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199. 330 $aSystemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease. 606 $aSystemic scleroderma 606 $aScleroderma, Systemic$xdiagnosis$vCase Reports 606 $aScleroderma, Systemic$xtherapy$vCase Reports 615 0$aSystemic scleroderma. 615 0$aScleroderma, Systemic$xdiagnosis 615 0$aScleroderma, Systemic$xtherapy 676 $a616.544 702 $aTomcik$b Michal 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910647231703321 996 $aFrontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis$93017846 997 $aUNINA LEADER 00501nas 2200169z- 450 001 9910978290503321 035 $a(CKB)5670000001016727 035 $a(EXLCZ)995670000001016727 100 $a20250218cuuuuuuuu -u- - 101 0 $aeng 200 00$aRechenschaftsbericht : für die Jahre / Badischer Landesverein vom Roten Kreuz 210 $cReiff 517 $aRechenschaftsbericht 906 $aJOURNAL 912 $a9910978290503321 996 $aRechenschaftsbericht : für die Jahre$94320081 997 $aUNINA